




CHEMBIOMOL-01: Chem. Biol. & Med. Chem. Workshop, Rostock, Germany-Bilbao, Spain-Galveston, Texas, USA, 2020

MOL2NET, International Conference Series on Multidisciplinary Sciences



CRISPR-Cas Genome Editing: Bioethical and Regulatory Issues

Dr. [Aliuska Duardo-Sanchez](#) (Law.Lic., Ph.D. TICs & Legal Sciences)

[PANELFIT](#) European Commission Project Manager.

Research Group: [Chair in Law and The Human Genome](#),

Dept. of Public Law, University of Basque Country (UPV/EHU), Campus Biscay, Leioa 48940, Spain.

Abstract. In a previous work we discussed about the concerns emerging worldwide related to the now widespread use of CRISPR-Cas genome editions' technique. This technique is a very important tool in molecular biology now a days and is called to become an important tool in Molecular Pharmacology, Personalized Medicines, and Synthetic Biology. In Drug Discovery and Medicinal Chemistry and Chemical Biology may be used for resistance-selection studies of antimicrobial compounds; research on druggability of new compounds, or implementation of new laboratory animal models for assay of new compounds. The implications for Biotechnology and dSynthetic Biology are more bizarre. Totally new compounds not existing in nature may be created in a very fast-track way. In our previous paper, we given an state-of-art discussion of literature with examples of CRISPR uses in chemical biology. We also discussed legal and ethical concerns still preset nowadays.

References

A. Duardo-Sanchez. CRISPR-Cas in Medicinal Chemistry: Applications and Regulatory Concerns *Curr Top Med Chem*, 2017;17(30):3308-3315.